Supplementary material

**5-HT1A Receptor Ligands and their Therapeutic Applications: Review of New Patents**

Table 1. 5-HT1A serotonin receptor modulators under development for neuropsychiatric disorders.\*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| No | Compound ID | Phase | Mechanism | Indication | Company |
| 1 | Eltoprazine | III | 5-HT1A/1BR agonist | ADHD  cognitive disorders | PsychoGenics |
| 2 | NCT00452504 | I | 5-HT1AR antagonist | Alzheimer’s disease | Pfizer |
| 3 | F-15599 | I | 5-HT1AR agonist | Cognitive disorders schizophrenia  mood disorder  Rett’s syndrome | Neurolixix |
| 4 | Piromelatine | II | 5-HT1R agonist,  melatonin MT1/2 agonist | Cognitive disorders | Neurim Pharmaceuticals |
| 5 | Naluzotan | II | 5-HT1AR agonist | Epilepsy/seizures (earlier MDD and GAD) | Epix Pharmaceuticals |
| 6 | TGFK-08AA | II | 5-HT1A receptor modulator | GAD | Fabre-Kramer Pharmaceuticals |
| 7 | Travivo, (Gepiron) | II | 5-HT1AR partial agonist  5-HT1AR,  5-HT2AR partial agonist | GAD | Fabre-Kramer Pharmaceuticals |
| 8 | FKW00GA | II | 5HT1AR partial agonist 5HT2R antagonist | GAD | Fabre-Kramer Pharmaceuticals |
| 9 | TGBA01AD | II | 5-HT1AR, 5-HT2R agonist  5-HT1DR modulator  Serotonin reuptake inhibitor | MDD | Fabre-Kramer Pharmaceuticals |
| 10 | MIN-117 | II | 5-HT1AR, 5-HT2AR antagonist | MDD | Minerva Neurosciences |
| 11 | Hypidone Hydrochloride | II | 5-HT1AR partial agonist Serotonin reuptake inhibitor | MDD | Huahai Pharmaceutical |
| 12 | FKB01MD | II | Serotonin reuptake inhibitor 5HT2R agonist 5HT1AR agonist 5HT1DR modulator | MDD | Fabre-Kramer Pharmaceuticals |
| 13 | Piclozotan | II | 5-HT1AR agonist | Parkinson’s disease | Daiichi Sankyo |
| 14 | Sarizotan | II | 5-HT1AR and D2R agonist | Rett’s syndrome | Newron Pharmaceuticals |
| 15 | F-17464 | II | D3R antagonist  5-HT1AR agonist | Schizophrenia | Pierre Fabre Pharmaceutical |
| 16 | F-17464 | II | D3R antagonist  5-HT1AR partial agonist | Schizophrenia | Pierre Fabre Pharmaceutical |
| 17 | RP-5063 | III | D2R, D3R, D4R partial agonist 5-HT1AR, 5-HT2AR partial agonist 5-HT6R, 5-HT7R antagonist | Schizophrenia | Reviva Pharmaceuticals |
| 18 | SEP-363856 | II | 5-HT1AR, TAAR1 agonist | Schizophrenia, Parkinson’s disease | Sumitomo Dainippon Pharma |
| \* data from https://www.pharmacodia.com and companies web pages, *ADHD* - Attention Deficit Hyperactivity Disorder, MDD – Major Depressive Disorder, GAD – Generalized Anxiety Disorder | | | | | |